<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400322</url>
  </required_header>
  <id_info>
    <org_study_id>MV20145</org_study_id>
    <secondary_id>Eudra CT: 2006-002022-29</secondary_id>
    <nct_id>NCT00400322</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection</brief_title>
  <official_title>A Randomized Double Blind Controlled Proof of Concept Study of the Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma With Successful Surgical Resection of at Least 90 % of the Initial Tumor and CMV Infection Demonstrated Histologically and Immunohistochemically.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if treatment of CMV infection by antiviral drug
      Valcyte (R) affects the clinical outcome of glioblastoma multiforme in patients with local
      CMV infection in tumor tissue. The investigators' hypothesis states that CMV infection
      promotes tumor development and disease progression and inhibits immune responses against the
      tumor.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">March 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor size</measure>
    <time_frame>week twelve and week twenty four</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease status</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Cytomegalovirus Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir (Valcyte)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glioblastoma grade IV

          -  Cytomegalovirus detected in tumor

          -  At least 90% resection of tumor

        Exclusion Criteria:

          -  Decreased kidney function

          -  Pregnancy

          -  Neutropenia

          -  Thrombocytopenia

          -  Patient not tolerating the drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inti Peredo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecilia Soderberg-Naucler, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of neurosurgery, Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <state>Stockholm</state>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Norrland University Hospital</name>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Akademiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2006</study_first_submitted>
  <study_first_submitted_qc>November 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2006</study_first_posted>
  <last_update_submitted>January 21, 2009</last_update_submitted>
  <last_update_submitted_qc>January 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2009</last_update_posted>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>cytomegalovirus infection</keyword>
  <keyword>antiviral treatment</keyword>
  <keyword>valganciclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

